Story

Novo Nordisk Stock Slides After Deutsche Bank Downgrade to 'Sell'

ENTHMSVIIDZHZH-TWJAKOHI
Aug 27, 20262 min read
Novo Nordisk Stock Slides After Deutsche Bank Downgrade to 'Sell'
Text size
Background

Shares of Novo Nordisk (NOVOb) declined on Tuesday after Deutsche Bank downgraded the pharmaceutical company's stock, amplifying investor concerns about its growth trajectory and competitive standing.

Deutsche Bank Cites Uncertainty

Deutsche Bank analyst Emmanuel Papadakis cut the rating on Novo Nordisk to 'Sell' from a previous 'Hold', making it one of the most bearish calls on the stock from a major investment bank. The firm also reduced its price target on the shares to 265 Danish kroner from 290 kroner.

The downgrade was prompted by what the bank described as mixed results from earlier in the month and "material uncertainty" ahead of Novo Nordisk's upcoming capital markets day. In response, the stock fell 2.4% to trade at 297.8 Danish kroner.

A Pattern of Investor Concern

The downgrade adds to a challenging backdrop for Novo Nordisk that has been building since its Q2 2026 earnings release on August 4. Despite management raising its full-year outlook, the stock sold off as investors focused on several underlying issues:

Sample IUX Markets – In-articleAd
  • The prescription trajectory for its key Wegovy pill came in slightly below analyst models.
  • The company reported pipeline disappointments, including the failed trial for its Ziltivekimab cardiovascular drug.

This sentiment was reinforced by a recent downgrade to 'Hold' from Berenberg on August 12. The cumulative weight of cautious analyst commentary has kept the stock significantly below its 52-week high of 410 kroner.

Competitive and Market Context

Pressure is also mounting from rival Eli Lilly, which is seen as widening its lead in the GLP-1 obesity drug market. Eli Lilly's oral weight-loss treatment received its first European regulatory approval in August, posing a direct challenge to Novo Nordisk's franchise.

Tuesday's decline in Novo Nordisk shares was company-specific, occurring while broader U.S. equity markets like the S&P 500 and Nasdaq posted modest gains. The Deutsche Bank note appeared to crystallize existing investor anxieties, sending the shares lower even as the company's share buyback program offered limited support.

Read next

More on Stocks
Back to latest news

LATEST